Is CGEN or TVGN more profitable?

Compugen has a net margin of 47.97% compared to Tevogen Bio's net margin of 0.00%. Compugen's return on equity of 47.72% beat Tevogen Bio's return on equity. Company Net Margins Return on Equity Return on Assets Compugen 47.97% 47.72% 27.51% Tevogen Bio N/A N/A -472.77%

Does the media favor CGEN or TVGN?

In the previous week, Tevogen Bio had 1 more articles in the media than Compugen. MarketBeat recorded 4 mentions for Tevogen Bio and 3 mentions for Compugen. Tevogen Bio's average media sentiment score of 0.97 beat Compugen's score of 0.62 indicating that Tevogen Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tevogen Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is KPTI or TVGN more profitable?

Tevogen Bio has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics -129.02% N/A -120.29% Tevogen Bio N/A N/A -472.77%

Do analysts recommend TVGN or JMAC?

Tevogen Bio presently has a consensus price target of $100.00, indicating a potential upside of 865.72%. Given Tevogen Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Tevogen Bio is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, TVGN or JMAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tevogen Bio N/A N/A -$26.27M -$4.61 N/A Maxpro Capital Acquisition N/A N/A N/A N/A N/A

Is TVGN or JMAC more profitable?

Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -472.77% Maxpro Capital Acquisition N/A N/A N/A

Does the media prefer TVGN or TNXP?

In the previous week, Tonix Pharmaceuticals had 4 more articles in the media than Tevogen Bio. MarketBeat recorded 8 mentions for Tonix Pharmaceuticals and 4 mentions for Tevogen Bio. Tonix Pharmaceuticals' average media sentiment score of 1.14 beat Tevogen Bio's score of 0.97 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tevogen Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tonix Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TVGN or CNTN?

Tevogen Bio currently has a consensus price target of $100.00, suggesting a potential upside of 865.72%. Given Tevogen Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Tevogen Bio is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, TVGN or CNTN?

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tevogen Bio N/A N/A -$26.27M -$4.61 N/A Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A

Is TVGN or CNTN more profitable?

Tevogen Bio's return on equity of 0.00% beat Hillstream Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -472.77% Hillstream Biopharma N/A -31.50% -24.72%

Tevogen Bio (TVGN) Competitors

$10.36 -0.12 (-1.10%)

As of 10:48 AM Eastern

Compare

TVGN vs. CGEN, KPTI, JMAC, TNXP, and CNTN

Should you buy Tevogen Bio stock or one of its competitors? MarketBeat compares Tevogen Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tevogen Bio include Compugen (CGEN), Karyopharm Therapeutics (KPTI), Maxpro Capital Acquisition (JMAC), Tonix Pharmaceuticals (TNXP), and Hillstream Biopharma (CNTN). These companies are all part of the "pharmaceutical products" industry.

How does Tevogen Bio compare to Compugen?

Compugen (NASDAQ:CGEN) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Compugen has a net margin of 47.97% compared to Tevogen Bio's net margin of 0.00%. Compugen's return on equity of 47.72% beat Tevogen Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.97%	47.72%	27.51%
Tevogen Bio	N/A	N/A	-472.77%

12.2% of Compugen shares are owned by institutional investors. 9.5% of Compugen shares are owned by company insiders. Comparatively, 70.5% of Tevogen Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Compugen currently has a consensus price target of $5.00, indicating a potential upside of 145.70%. Tevogen Bio has a consensus price target of $100.00, indicating a potential upside of 865.72%. Given Tevogen Bio's higher probable upside, analysts plainly believe Tevogen Bio is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Tevogen Bio had 1 more articles in the media than Compugen. MarketBeat recorded 4 mentions for Tevogen Bio and 3 mentions for Compugen. Tevogen Bio's average media sentiment score of 0.97 beat Compugen's score of 0.62 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tevogen Bio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compugen has higher revenue and earnings than Tevogen Bio. Tevogen Bio is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	2.64	$35.34M	$0.37	5.50
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A

Compugen has a beta of 2.74, suggesting that its stock price is 174% more volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.14, suggesting that its stock price is 86% less volatile than the broader market.

Summary

Compugen beats Tevogen Bio on 12 of the 16 factors compared between the two stocks.

How does Tevogen Bio compare to Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Karyopharm Therapeutics currently has a consensus price target of $17.17, suggesting a potential upside of 82.68%. Tevogen Bio has a consensus price target of $100.00, suggesting a potential upside of 865.72%. Given Tevogen Bio's higher probable upside, analysts plainly believe Tevogen Bio is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Tevogen Bio has lower revenue, but higher earnings than Karyopharm Therapeutics. Tevogen Bio is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	1.46	-$196.04M	-$15.09	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A

Tevogen Bio has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-129.02%	N/A	-120.29%
Tevogen Bio	N/A	N/A	-472.77%

66.4% of Karyopharm Therapeutics shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 70.5% of Tevogen Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Tevogen Bio had 3 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 4 mentions for Tevogen Bio and 1 mentions for Karyopharm Therapeutics. Tevogen Bio's average media sentiment score of 0.97 beat Karyopharm Therapeutics' score of 0.94 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Karyopharm Therapeutics	Positive
Tevogen Bio	Positive

Karyopharm Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.14, suggesting that its share price is 86% less volatile than the broader market.

Summary

Karyopharm Therapeutics beats Tevogen Bio on 8 of the 15 factors compared between the two stocks.

How does Tevogen Bio compare to Maxpro Capital Acquisition?

Tevogen Bio (NASDAQ:TVGN) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. 70.5% of Tevogen Bio shares are owned by company insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Tevogen Bio had 4 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 4 mentions for Tevogen Bio and 0 mentions for Maxpro Capital Acquisition. Tevogen Bio's average media sentiment score of 0.97 beat Maxpro Capital Acquisition's score of 0.00 indicating that Tevogen Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Tevogen Bio	Positive
Maxpro Capital Acquisition	Neutral

Tevogen Bio presently has a consensus price target of $100.00, indicating a potential upside of 865.72%. Given Tevogen Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Tevogen Bio is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Tevogen Bio has a beta of 0.14, suggesting that its stock price is 86% less volatile than the broader market. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-472.77%
Maxpro Capital Acquisition	N/A	N/A	N/A

Summary

Tevogen Bio beats Maxpro Capital Acquisition on 6 of the 8 factors compared between the two stocks.

How does Tevogen Bio compare to Tonix Pharmaceuticals?

Tevogen Bio (NASDAQ:TVGN) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

In the previous week, Tonix Pharmaceuticals had 4 more articles in the media than Tevogen Bio. MarketBeat recorded 8 mentions for Tonix Pharmaceuticals and 4 mentions for Tevogen Bio. Tonix Pharmaceuticals' average media sentiment score of 1.14 beat Tevogen Bio's score of 0.97 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tevogen Bio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tonix Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tevogen Bio has higher earnings, but lower revenue than Tonix Pharmaceuticals. Tevogen Bio is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A
Tonix Pharmaceuticals	$13.11M	14.22	-$124.02M	-$14.36	N/A

Tevogen Bio presently has a consensus target price of $100.00, suggesting a potential upside of 865.72%. Tonix Pharmaceuticals has a consensus target price of $22.00, suggesting a potential upside of 88.07%. Given Tevogen Bio's higher probable upside, research analysts clearly believe Tevogen Bio is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 70.5% of Tevogen Bio shares are held by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tevogen Bio has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Tevogen Bio's return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-472.77%
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%

Tevogen Bio has a beta of 0.14, suggesting that its share price is 86% less volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market.

Summary

Tonix Pharmaceuticals beats Tevogen Bio on 9 of the 15 factors compared between the two stocks.

How does Tevogen Bio compare to Hillstream Biopharma?

Tevogen Bio (NASDAQ:TVGN) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

Tevogen Bio has a beta of 0.14, indicating that its stock price is 86% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

Tevogen Bio currently has a consensus price target of $100.00, suggesting a potential upside of 865.72%. Given Tevogen Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Tevogen Bio is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tevogen Bio's return on equity of 0.00% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-472.77%
Hillstream Biopharma	N/A	-31.50%	-24.72%

1.2% of Hillstream Biopharma shares are held by institutional investors. 70.5% of Tevogen Bio shares are held by company insiders. Comparatively, 6.7% of Hillstream Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Tevogen Bio had 3 more articles in the media than Hillstream Biopharma. MarketBeat recorded 4 mentions for Tevogen Bio and 1 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 1.89 beat Tevogen Bio's score of 0.97 indicating that Hillstream Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Tevogen Bio	Positive
Hillstream Biopharma	Very Positive

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A

Summary

Tevogen Bio beats Hillstream Biopharma on 7 of the 12 factors compared between the two stocks.

Get Tevogen Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TVGN vs. The Competition

Export

Metric	Tevogen Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$43.33M	$3.39B	$6.49B	$12.31B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-2.26	20.05	24.05	24.76
Price / Sales	N/A	325.48	542.61	168.32
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	-0.05	8.16	10.69	6.90
Net Income	-$26.27M	$23.89M	$3.57B	$337.45M
7 Day Performance	-11.04%	3.66%	1.56%	2.84%
1 Month Performance	30.25%	1.69%	2.49%	4.78%
1 Year Performance	-83.30%	46.95%	26.51%	33.08%

Tevogen Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TVGN Tevogen Bio	2.2525 of 5 stars	$10.36 -1.1%	$100.00 +865.7%	-83.1%	$43.33M	N/A	N/A	3	Gap Up
CGEN Compugen	3.9312 of 5 stars	$2.02 -1.0%	$5.00 +147.5%	+24.4%	$192.89M	$72.76M	5.46	70
KPTI Karyopharm Therapeutics	2.4117 of 5 stars	$8.69 +2.2%	$17.17 +97.5%	+116.4%	$192.63M	$146.07M	N/A	380	Gap Down
JMAC Maxpro Capital Acquisition	N/A	$14.00 flat	N/A	+135.6%	$187.99M	N/A	N/A	2,021
TNXP Tonix Pharmaceuticals	4.0346 of 5 stars	$11.46 -2.1%	$22.00 +92.0%	-64.5%	$186.67M	$13.11M	N/A	50	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TVGN) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tevogen Bio (TVGN) Competitors

TVGN vs. CGEN, KPTI, JMAC, TNXP, and CNTN

How does Tevogen Bio compare to Compugen?

Summary

How does Tevogen Bio compare to Karyopharm Therapeutics?

Summary

How does Tevogen Bio compare to Maxpro Capital Acquisition?

Summary

How does Tevogen Bio compare to Tonix Pharmaceuticals?

Summary

How does Tevogen Bio compare to Hillstream Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN vs. The Competition

Tevogen Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tevogen Bio (TVGN) Competitors

TVGN vs. CGEN, KPTI, JMAC, TNXP, and CNTN

How does Tevogen Bio compare to Compugen?

Is CGEN or TVGN more profitable?

Do institutionals and insiders have more ownership in CGEN or TVGN?

Do analysts prefer CGEN or TVGN?

Does the media favor CGEN or TVGN?

Which has stronger valuation and earnings, CGEN or TVGN?

Which has more volatility and risk, CGEN or TVGN?

Summary

How does Tevogen Bio compare to Karyopharm Therapeutics?

Do analysts prefer KPTI or TVGN?

Which has higher valuation and earnings, KPTI or TVGN?

Is KPTI or TVGN more profitable?

Do institutionals & insiders hold more shares of KPTI or TVGN?

Does the media favor KPTI or TVGN?

Which has more volatility & risk, KPTI or TVGN?

Summary

How does Tevogen Bio compare to Maxpro Capital Acquisition?

Do insiders and institutionals believe in TVGN or JMAC?

Does the media refer more to TVGN or JMAC?

Do analysts recommend TVGN or JMAC?

Which has more volatility & risk, TVGN or JMAC?

Which has better valuation and earnings, TVGN or JMAC?

Is TVGN or JMAC more profitable?

Summary

How does Tevogen Bio compare to Tonix Pharmaceuticals?

Does the media prefer TVGN or TNXP?

Which has stronger earnings & valuation, TVGN or TNXP?

Do analysts prefer TVGN or TNXP?

Do insiders and institutionals have more ownership in TVGN or TNXP?

Is TVGN or TNXP more profitable?

Which has more volatility & risk, TVGN or TNXP?

Summary

How does Tevogen Bio compare to Hillstream Biopharma?

Which has more volatility & risk, TVGN or CNTN?

Do analysts prefer TVGN or CNTN?

Is TVGN or CNTN more profitable?

Do insiders and institutionals hold more shares of TVGN or CNTN?

Does the media refer more to TVGN or CNTN?

Which has better earnings & valuation, TVGN or CNTN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN vs. The Competition

Tevogen Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools